Nexgel, Inc · NASDAQ:NXGL
Nexgel — Q3 2025 Earnings Presentation
17 slides from Nexgel's earnings presentation, Nov 12, 2025
Slide 1: NEXGEL Investor Presentation November 2025
@NEXCEL @ NEXGEL anced hydrogel solutions Investor Presen November 2025 | | NASDAQ: NXGL \
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and
Slide 3: NEXGEL - Who We Are and What We Do
NEXGEL - Who We Are and What We Do After two decades of creating custom hydrogel Agreements with Multi-Billion solutions for large medical device companies, our Dollar Corporations business today includes the development of patented medical devices, custom/white label == products, and OTC healthcare
Slide 4: Multiple Products & Applications for Nexgel's Technology
Multiple Products & Applications for Nexgel’s Technology Medical Device NEXGEL Is addressing the importance of skin integrity and overall skincare with a medical device licensing model Custom & White Label Bringing proven medical-grade technology to OTC and Beauty & Cosmetics for the first time thro
Slide 5: Competitive Advantage: State-of-the-Art Manufacturing Facilities in NA
Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments 1 of 2 manufacturing facilities 16,500-square-
Slide 6: Converting and Packaging Facility
Converting and Packaging Facility 50% ownership in converting and packaging business in Granbury, Texas + Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts - Increased square footage and installed cutti
Slide 7: Hydrogels for Consumer and Medical Applications
Hydrogels for Consumer and Medical Applications + Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers * Gentle formula
Slide 8: Current Medical Device Pipeline
Current Medical Device Pipeline Addressing the importance of skin integrity and overall skincare with a medical device @NEXGEL NASDAQ; NXGL \ \ x /\ |
Slide 9: Medical Device Pipeline: Drug Delivery
Medical Device Pipeline: Drug Delivery Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology Drug Delivery: Diclofenac Patch To treat short-term pain due to preclinical sprains and bruises Drug Delivery: Apremilast Patch co Pera turn fromnleXeEl Pachaners Hau To treat
Slide 10: Consumer Health & Beauty
Consumer Health & Beauty Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications | | @NEXGEL NASDAQ: NXGL \
Slide 11: NEXGEL Branded Products
NEXGEL Branded Products @NEXGEL NASDAQ: NXGL
Slide 12: M&A Strategy: Consumer Brand Acquisition
M&A Strategy: Consumer Brand Acquisition Kenkoderm Skincare Line Silly George Beauty Brand + Acquisition completed in December 2023 + Acquisition completed in May 2024 + Complimentary line of alternative psoriasis treatments * Specialty eye and eyelash consumer product line + Profitable (ttm) and im
Slide 13: Cintas Corporation
Cintas Corporation Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America + Cintas will distribute SilverSeal, NEXGEL's hospital-grade dressing for wounds and burns to its customers in many sectors inc
Slide 14: STADA Arzneimittel AG
STADA Arzneimittel AG Partnership with a leading European consumer health company accelerates the expansion of NEXGEL’s OTC product portfolio + STADA, a global leader in consumer healthcare, generics, and specialty pharmaceuticals with sales in ~120 countries, is using this partnership to establish
Slide 15: New Partnerships & Customers
New Partnerships & Customers Reducing Carcinogenic Plume in Laser Hair Removal An FDA-compliant IRB study conducted by Innovative Optics evaluating NEXGEL hydrogel's efficacy in reducing harmful plume during laser hair removal. 30-patient trial at Florida Clinical Research Center. Data publication s
Slide 16: Revenue for Q3'25
Revenue for Q3’25 $2.94M —$3.04M_—$2.81M_—«$288M_——«$2.93M. 4141% YOY +181%YOY +121% YOY +100%YOY -0.2% YOY $3,000 $2,500 $2,000 s1.4am $1,500 gam #23%YOY Sioa, “20836 YOY 110% YOY $1,000 Previous TTM TT™ $500 Revenue: Revenue: $6.7M $1L.7M inthousands 042023 012024 022024 32024 4202412025 422025032
Slide 17: Contact Us
Contact Us Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director PH: (212) 896-1254 NEXGEL@KCSA.com \ @NEXGEL NASDAQ: NXGL